Provided by Tiger Trade Technology Pte. Ltd.

CARSGEN-B

13.360
+0.1501.14%
Volume:1.90M
Turnover:25.06M
Market Cap:7.94B
PE:-75.37
High:13.410
Open:13.330
Low:12.950
Close:13.210
52wk High:28.600
52wk Low:10.870
Shares:594.00M
HK Float Shares:594.00M
Volume Ratio:0.48
T/O Rate:0.32%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.177
ROE:-9.57%
ROA:-8.99%
PB:6.18
PE(LYR):-75.37
PS:49.78

Loading ...

CARsgen Therapeutics (SEHK:2171) Stock Carries Premium Valuation Despite Ongoing Losses

Simply Wall St.
·
Aug 19

CARSGEN-B Surges Nearly 5% Post-Earnings as Mid-Year Revenue Climbs 21.5% to RMB 61.9 Million

Deep News
·
Aug 19

Press Release: CARsgen Therapeutics Announces 2026 Interim Results

Dow Jones
·
Aug 19

CARsgen Therapeutics Holdings (SEHK:2171) Gains On CT0596 IND Clearance, But Is The Valuation Too Rich

Simply Wall St.
·
Aug 19

CARsgen Therapeutics posts narrower interim loss; revenue up 21.5% on BCMA CAR-T sales, cash boosted by HK$462 million placing

Bulletin Express
·
Aug 18

CARsgen-B Posts Interim Results with 11.52% Narrower Loss Attributable to Owners

Stock News
·
Aug 18

CARsgen FY26 H1 Net Loss Narrows to RMB 70.84 Million; Revenue Rises 21.49% to RMB 61.92 Million

Reuters
·
Aug 18

CARsgen Therapeutics Wins China IND Clearance for Lymphoma Cell Therapy

MT Newswires Live
·
Aug 07

CARSGEN-B (02171) Surges Over 4% as CT1190B Gets IND Nod for R/R LBCL Patients After Second-Line Failure

Stock News
·
Aug 07

CARSGEN-B Receives IND Clearance from Chinese Drug Regulator for Novel Cell Therapy Targeting Lymphoma

Stock News
·
Aug 07

CARsgen Says NMPA Clears IND for Ct1190b in Relapsed/refractory Large B-Cell Lymphoma

Reuters
·
Aug 07

CARsgen Therapeutics - Ct1190b Receives Ind Clearance from Nmpa for Relapsed/Refractory Large B-Cell Lymphoma

THOMSON REUTERS
·
Aug 07

CARsgen Schedules 18 Aug 2026 Board Meeting to Approve 1H 2026 Interim Results

Bulletin Express
·
Aug 06

CARsgen Therapeutics Schedules Board Meeting to Review Interim Results

Reuters
·
Aug 06

CARsgen Therapeutics Receives China IND Clearance for Multiple Myeloma Therapy; Shares Up 3%

MT Newswires Live
·
Aug 04

Carsgen Therapeutics Says Ct0596 Receives IND Clearance from NMPA

Reuters
·
Aug 04

China's Nod Granted to CARSGEN-B's BCMA-Targeting Universal CAR-T for Hard-to-Treat Myeloma

Stock News
·
Aug 04

CARsgen Secures NMPA IND Clearance for Allogeneic BCMA CAR-T Candidate CT0596 in Relapsed/Refractory Multiple Myeloma

Bulletin Express
·
Aug 04

CARsgen Says Ct0596 Wins NMPA IND Clearance for Relapsed/refractory Multiple Myeloma

Reuters
·
Aug 04

CARsgen Therapeutics - Ct0596 Receives Ind Clearance from Nmpa for Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Aug 04